Search the GHTC website

Global health R&D delivers for Alabama

US government investment in global health R&D has delivered

$68.7 million
to Alabama research institutions
850+ new jobs
for Alabama
Global health R&D at work in Alabama

The University of Alabama at Birmingham School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, SARS, chikungunya, and dengue. Researchers work to target and inhibit enzymes essential for viral replication. The viruses AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, with West Nile virus and influenza routinely infecting US citizens. Southern Research Institute in Birmingham is supporting AD3C in screening potential compounds.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: NIAID